Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated Retinopathy Patient

TL;DR

This case report tracks a patient with melanoma-associated retinopathy over time, revealing how autoantibodies affect vision and how treatment with corticosteroids can help.

Contribution

The study provides longitudinal insights into MAR pathogenesis and treatment response, showing corticosteroids can alleviate symptoms despite high autoantibody levels.

Findings

TRPM1 autoantibodies can impair vision even at low serum levels detectable by western blot and immunohistochemistry.

Intraocular dexamethasone treatment alleviates MAR symptoms despite high circulating TRPM1 autoantibody levels.

Elevated inflammatory cytokines may damage the blood-retinal barrier, allowing autoantibodies to enter the retina.

Abstract

Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome associated with cutaneous metastatic melanoma in which patients develop vision deficits that include reduced night vision, poor contrast sensitivity, and photopsia. MAR is caused by autoantibodies targeting TRPM1, an ion channel found in melanocytes and retinal ON-bipolar cells (ON-BCs). The visual symptoms arise when TRPM1 autoantibodies enter ON-BCs and block the function of TRPM1, thus detection of TRPM1 autoantibodies in patient serum is a key criterion in diagnosing MAR. Electroretinograms are used to measure the impact of TRPM1 autoantibodies on ON-BC function and represent another important diagnostic tool for MAR. To date, MAR case reports have included one or both diagnostic components, but only for a single time point in the course of a patient’s disease. Here, we report a case of MAR supported by longitudinal analysis of serum autoantibody detection, visual function, ocular inflammation, vascular integrity, and response to slow-release intraocular corticosteroids. Integrating these data with the patient’s oncological and ophthalmological records reveals novel insights regarding MAR pathogenesis, progression, and treatment, which may inform new research and expand our collective understanding of the disease. In brief, we find TRPM1 autoantibodies can disrupt vision even when serum levels are barely detectable by western blot and immunohistochemistry; intraocular dexamethasone treatment alleviates MAR visual symptoms despite high levels of circulating TRPM1 autoantibodies, implicating antibody access to the retina as a key factor in MAR pathogenesis. Elevated inflammatory cytokine levels in the patient’s eyes may be responsible for the observed damage to the blood-retinal barrier and subsequent entry of autoantibodies into the retina.

Figures